Sionna Therapeutics (SION) EBITDA (2024 - 2026)

Sionna Therapeutics has disclosed EBITDA across 3 years of filings, most recently posting -$27.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$27.4 million, down 65.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$86.0 million (down 30.2% YoY), and the FY2025 annual result was -$75.1 million, down 22.47% from the prior year.
• EBITDA came in at -$27.4 million for Q1 2026 at Sionna Therapeutics, down from -$20.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$8.7 million in Q2 2024 to a low of -$27.4 million in Q1 2026.
• The 3-year median for EBITDA is -$18.2 million (2025), against an average of -$18.2 million.
• Peak annual rise in EBITDA reached 18.24% in 2025, while the deepest fall reached 109.03% in 2025.
• Sionna Therapeutics' EBITDA stood at -$16.3 million in 2024, then retreated by 25.02% to -$20.3 million in 2025, then tumbled by 34.86% to -$27.4 million in 2026.
• The last three EBITDA figures came in at -$27.4 million (Q1 2026), -$20.3 million (Q4 2025), and -$20.0 million (Q3 2025), per Business Quant data.